Hence, we used a KRAS- and SMAD4-wild-type colorectal adenocarcinoma cell line, SW48, and its genetically engineered derivative carrying the activating KRASG12D allele. This evidence concerns the gene SMAD4 and colorectal adenocarcinoma.